Cargando…

Alpha Lipoic Acid for Symptomatic Peripheral Neuropathy in Patients with Diabetes: A Meta-Analysis of Randomized Controlled Trials

Objective. We performed a systematic review of the literature to evaluate the effects of alpha lipoic acid for symptomatic peripheral neuropathy in patients with diabetes mellitus. Research design and methods. The databases MEDLINE and EMBASE were searched using the key words “lipoic acid”, “thiocti...

Descripción completa

Detalles Bibliográficos
Autores principales: Mijnhout, Gerritje S., Kollen, Boudewijn J., Alkhalaf, Alaa, Kleefstra, Nanno, Bilo, Henk J. G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3272801/
https://www.ncbi.nlm.nih.gov/pubmed/22331979
http://dx.doi.org/10.1155/2012/456279
_version_ 1782222839508631552
author Mijnhout, Gerritje S.
Kollen, Boudewijn J.
Alkhalaf, Alaa
Kleefstra, Nanno
Bilo, Henk J. G.
author_facet Mijnhout, Gerritje S.
Kollen, Boudewijn J.
Alkhalaf, Alaa
Kleefstra, Nanno
Bilo, Henk J. G.
author_sort Mijnhout, Gerritje S.
collection PubMed
description Objective. We performed a systematic review of the literature to evaluate the effects of alpha lipoic acid for symptomatic peripheral neuropathy in patients with diabetes mellitus. Research design and methods. The databases MEDLINE and EMBASE were searched using the key words “lipoic acid”, “thioctic acid”, “diabet(∗)”, and the MeSH-terms “thioctic acid” and “diabetes mellitus”. Randomised controlled trials using the TSS score as the outcome measure were selected and assessed for their methodological quality. Study selection and quality assessment were performed independently by three observers. Results. Overall, the pooled standardized mean difference estimated from all trials revealed a reduction in TSS scores of −2.26 (CI: −3.12 to −1.41; P = 0.00001) in favour of alpha lipoic acid administration. Subgroup analyses of oral administration (−1.78 CI: −2.45 to −1.10; P = 0.00001) and intravenous administration (−2.81 CI: −4.16 to −1.46; P = 0.0001) confirmed the robustness of the overall result. Conclusions. When given intravenously at a dosage of 600 mg/day over a period of 3 weeks, alpha lipoic acid leads to a significant and clinically relevant reduction in neuropathic pain (grade of recommendation A). It is unclear if the significant improvements seen after 3–5 weeks of oral administration at a dosage of >600 mg/day are clinically relevant.
format Online
Article
Text
id pubmed-3272801
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-32728012012-02-13 Alpha Lipoic Acid for Symptomatic Peripheral Neuropathy in Patients with Diabetes: A Meta-Analysis of Randomized Controlled Trials Mijnhout, Gerritje S. Kollen, Boudewijn J. Alkhalaf, Alaa Kleefstra, Nanno Bilo, Henk J. G. Int J Endocrinol Review Article Objective. We performed a systematic review of the literature to evaluate the effects of alpha lipoic acid for symptomatic peripheral neuropathy in patients with diabetes mellitus. Research design and methods. The databases MEDLINE and EMBASE were searched using the key words “lipoic acid”, “thioctic acid”, “diabet(∗)”, and the MeSH-terms “thioctic acid” and “diabetes mellitus”. Randomised controlled trials using the TSS score as the outcome measure were selected and assessed for their methodological quality. Study selection and quality assessment were performed independently by three observers. Results. Overall, the pooled standardized mean difference estimated from all trials revealed a reduction in TSS scores of −2.26 (CI: −3.12 to −1.41; P = 0.00001) in favour of alpha lipoic acid administration. Subgroup analyses of oral administration (−1.78 CI: −2.45 to −1.10; P = 0.00001) and intravenous administration (−2.81 CI: −4.16 to −1.46; P = 0.0001) confirmed the robustness of the overall result. Conclusions. When given intravenously at a dosage of 600 mg/day over a period of 3 weeks, alpha lipoic acid leads to a significant and clinically relevant reduction in neuropathic pain (grade of recommendation A). It is unclear if the significant improvements seen after 3–5 weeks of oral administration at a dosage of >600 mg/day are clinically relevant. Hindawi Publishing Corporation 2012 2012-01-26 /pmc/articles/PMC3272801/ /pubmed/22331979 http://dx.doi.org/10.1155/2012/456279 Text en Copyright © 2012 Gerritje S. Mijnhout et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Mijnhout, Gerritje S.
Kollen, Boudewijn J.
Alkhalaf, Alaa
Kleefstra, Nanno
Bilo, Henk J. G.
Alpha Lipoic Acid for Symptomatic Peripheral Neuropathy in Patients with Diabetes: A Meta-Analysis of Randomized Controlled Trials
title Alpha Lipoic Acid for Symptomatic Peripheral Neuropathy in Patients with Diabetes: A Meta-Analysis of Randomized Controlled Trials
title_full Alpha Lipoic Acid for Symptomatic Peripheral Neuropathy in Patients with Diabetes: A Meta-Analysis of Randomized Controlled Trials
title_fullStr Alpha Lipoic Acid for Symptomatic Peripheral Neuropathy in Patients with Diabetes: A Meta-Analysis of Randomized Controlled Trials
title_full_unstemmed Alpha Lipoic Acid for Symptomatic Peripheral Neuropathy in Patients with Diabetes: A Meta-Analysis of Randomized Controlled Trials
title_short Alpha Lipoic Acid for Symptomatic Peripheral Neuropathy in Patients with Diabetes: A Meta-Analysis of Randomized Controlled Trials
title_sort alpha lipoic acid for symptomatic peripheral neuropathy in patients with diabetes: a meta-analysis of randomized controlled trials
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3272801/
https://www.ncbi.nlm.nih.gov/pubmed/22331979
http://dx.doi.org/10.1155/2012/456279
work_keys_str_mv AT mijnhoutgerritjes alphalipoicacidforsymptomaticperipheralneuropathyinpatientswithdiabetesametaanalysisofrandomizedcontrolledtrials
AT kollenboudewijnj alphalipoicacidforsymptomaticperipheralneuropathyinpatientswithdiabetesametaanalysisofrandomizedcontrolledtrials
AT alkhalafalaa alphalipoicacidforsymptomaticperipheralneuropathyinpatientswithdiabetesametaanalysisofrandomizedcontrolledtrials
AT kleefstrananno alphalipoicacidforsymptomaticperipheralneuropathyinpatientswithdiabetesametaanalysisofrandomizedcontrolledtrials
AT bilohenkjg alphalipoicacidforsymptomaticperipheralneuropathyinpatientswithdiabetesametaanalysisofrandomizedcontrolledtrials